In Vitro Activity of Nemonoxacin, a Novel Nonfluorinated Quinolone, against 2,440 Clinical Isolates

Adam, Heather J.; Laing, Nancy M.; King, Chi-Hsin R.; Lulashnyk, Ben; Hoban, Daryl J.; Zhanel, George G.

doi:10.1128/aac.00078-09

Cited by 67 publications

(73 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has completed phase 2 studies for community-acquired pneumonia (CAP) and for diabetic foot infections; recruitment is in progress for a phase 3 trial in CAP (http://www.clinicaltrials.gov). Nemonoxacin has a broad spectrum of activity against Gram-positive, Gram-negative, and atypical pathogens, including activity against methicillin-resistant Staphylococcus aureus (MRSA) (MIC 90 ϭ 1 g/ml) and vancomycin-resistant pathogens (17,18). However, it was less active against Gram-negative pathogens such as Escherichia coli, Proteus mirabilis, and Pseudomonas aeruginosa, with MIC 90 values of 32, 16, and 32 g/ml, respectively (18,19).…”

Section: Quinolonesmentioning

confidence: 99%

Investigational Antimicrobial Agents of 2013

Pucci

Bush

2013

Clin Microbiol Rev

View full text Add to dashboard Cite

SUMMARY New antimicrobial agents are always needed to counteract the resistant pathogens that continue to be selected by current therapeutic regimens. This review provides a survey of known antimicrobial agents that were currently in clinical development in the fall of 2012 and spring of 2013. Data were collected from published literature primarily from 2010 to 2012, meeting abstracts (2011 to 2012), government websites, and company websites when appropriate. Compared to what was reported in previous surveys, a surprising number of new agents are currently in company pipelines, particularly in phase 3 clinical development. Familiar antibacterial classes of the quinolones, tetracyclines, oxazolidinones, glycopeptides, and cephalosporins are represented by entities with enhanced antimicrobial or pharmacological properties. More importantly, compounds of novel chemical structures targeting bacterial pathways not previously exploited are under development. Some of the most promising compounds include novel β-lactamase inhibitor combinations that target many multidrug-resistant Gram-negative bacteria, a critical medical need. Although new antimicrobial agents will continue to be needed to address increasing antibiotic resistance, there are novel agents in development to tackle at least some of the more worrisome pathogens in the current nosocomial setting.

show abstract

Section: Quinolonesmentioning

confidence: 99%

Investigational Antimicrobial Agents of 2013

Pucci

Bush

2013

Clin Microbiol Rev

View full text Add to dashboard Cite

show abstract

“…The activity spectrum profiles of several newer quinolones in clinical trials (e.g., the fluoroquinolones delafloxacin, finafloxacin, and JNJ-Q2; the nonfluorinated quinolone nemonoxacin; and an isothiazoloquinolone, ACH-702) (944,(964)(965)(966)(967)(968) suggest that these agents are substrates of RND pumps. Nevertheless, although still a substrate of the A. baumannii AdeABC and AdeM pumps, a new broad-spectrum fluoroquinolone, DS-8587, was found to have better activity against AdeABC-or AdeM-overproducing mutants than ciprofloxacin and levofloxacin (969), further supported by its efficacy in an animal model (970).…”

Section: Multidrug Efflux Pumps As a Challenge In Drug Developmentmentioning

confidence: 99%

The Challenge of Efflux-Mediated Antibiotic Resistance in Gram-Negative Bacteria

2015

View full text Add to dashboard Cite

SUMMARY The global emergence of multidrug-resistant Gram-negative bacteria is a growing threat to antibiotic therapy. The chromosomally encoded drug efflux mechanisms that are ubiquitous in these bacteria greatly contribute to antibiotic resistance and present a major challenge for antibiotic development. Multidrug pumps, particularly those represented by the clinically relevant AcrAB-TolC and Mex pumps of the resistance-nodulation-division (RND) superfamily, not only mediate intrinsic and acquired multidrug resistance (MDR) but also are involved in other functions, including the bacterial stress response and pathogenicity. Additionally, efflux pumps interact synergistically with other resistance mechanisms (e.g., with the outer membrane permeability barrier) to increase resistance levels. Since the discovery of RND pumps in the early 1990s, remarkable scientific and technological advances have allowed for an in-depth understanding of the structural and biochemical basis, substrate profiles, molecular regulation, and inhibition of MDR pumps. However, the development of clinically useful efflux pump inhibitors and/or new antibiotics that can bypass pump effects continues to be a challenge. Plasmid-borne efflux pump genes (including those for RND pumps) have increasingly been identified. This article highlights the recent progress obtained for organisms of clinical significance, together with methodological considerations for the characterization of MDR pumps.

show abstract

“…It is globally 2-8-fold more potent than moxifloxacin against most Gram-positive cocci but 4-fold less potent than ciprofloxacin against Gram-negative bacilli (116). Additionally, it also shows useful activity on Chlamydia spp.…”

Section: Quinolonesmentioning

confidence: 95%

Renaissance of antibiotics against difficult infections: Focus on oritavancin and new ketolides and quinolones

Bambeke

2014

Annals of Medicine

View full text Add to dashboard Cite

In Vitro Activity of Nemonoxacin, a Novel Nonfluorinated Quinolone, against 2,440 Clinical Isolates

Cited by 67 publications

References 13 publications

Investigational Antimicrobial Agents of 2013

Investigational Antimicrobial Agents of 2013

The Challenge of Efflux-Mediated Antibiotic Resistance in Gram-Negative Bacteria

Renaissance of antibiotics against difficult infections: Focus on oritavancin and new ketolides and quinolones

Contact Info

Product

Resources

About